An Open-Label, Multicenter Study to Assess the Potential Effects of Rifampin on the Pharmacokinetics of Trabectedin in Subjects With Advanced Malignancies.

Trial Profile

An Open-Label, Multicenter Study to Assess the Potential Effects of Rifampin on the Pharmacokinetics of Trabectedin in Subjects With Advanced Malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 30 May 2014

At a glance

  • Drugs Rifampicin (Primary) ; Trabectedin (Primary) ; Dexamethasone
  • Indications Malignant melanoma; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 12 Aug 2011 Actual initiation date changed from Feb 2011 to Dec 2010 and trial phase changed from I/II to I as reported by ClinicalTrials.gov.
    • 09 Jun 2011 Planned End Date changed from 1 Apr 2013 to 1 Feb 2013 as reported by ClinicalTrials.gov.
    • 19 May 2011 Planned end date changed from 1 Mar 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top